Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. announced that they have entered into an exclusive sales agreement. Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset's cGMP psilocybin to appropriately licensed clinical researchers. Mindset has recently completed production of a large batch of cGMP psilocybin at the U.S. site of an international contract development and manufacturing company pursuant to the annual DEA quota on psilocybin.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 CAD | 0.00% | +2.33% | +57.14% |
Apr. 19 | Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement | MT |
Apr. 19 | Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+57.14% | 13.97M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Mindset Pharma Inc. and Pharmala Biotech Holdings Inc. Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin